KEY TAKEAWAYS
- The study aimed to investigate the overall effectiveness and safety of CAR-T therapy in patients with R/R MCL across a broader cohort.
- Researchers noticed that CAR-T therapy provides effective treatment with manageable side effects for R/R MCL.
Chimeric antigen receptor (CAR) T-cell therapy (CAR-T therapy) has shown significant efficacy in the ZUMA-2 study. Following regulatory approvals, various clinical trials and real-world studies on CAR-T therapy for relapsed or refractory mantle cell lymphoma (R/R MCL) have been conducted. However, the data regarding clinical safety and efficacy remain inconsistent.
Haixiang Wan and the team aimed to systematically analyze CAR-T therapy’s effectiveness and safety across a broader and more representative cohort of patients with R/R MCL.
They performed an inclusive analysis of studies involving patients with R/R MCL who received CAR-T cell therapy. Data were systematically extracted and consolidated, primarily focusing on evaluating safety and efficacy outcome measures. This study has not been registered with PROSPERO.
About 16 studies involving 984 patients were identified and included in this meta-analysis. The pooled estimate for the overall response rate (ORR) was 89%, while the complete remission (CR) rate was 74%. The 6-month and 12-month progression-free survival (PFS) rates were 69% and 53%, respectively, and the overall survival (OS) rates were 80% and 69%, respectively.
Cytokine release syndrome (CRS) of grade 3 or higher was observed in 8% of patients, whereas neurotoxicity of grade 3 or higher was observed in 22% of patients. The risk of bias was assessed as low in 9 studies and moderate in 7 studies.
The study concluded that CAR-T therapy demonstrates promising efficacy and manageable adverse reactions in patients with R/R MCL, highlighting its potential as a viable treatment option.
The study is funded by the Jiangxi Province Key Science and Technology Cooperation Project.
Source: https://pubmed.ncbi.nlm.nih.gov/39308870/
Wan H, Weng S, Sheng S, Kuang Z, et al. (2024). “Chimeric antigen receptor T-cell therapy in relapsed or refractory mantle cell lymphoma: a systematic review and meta-analysis.” Front Immunol. 2024;15:1435127. Published 2024 Sep 6. doi:10.3389/fimmu.2024.1435127
